Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.
We're tracking Alto Neuroscience's market expansion
How Alto Neuroscience's international expansion compares to its competitors
Alto NeuroscienceYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Alto NeuroscienceYou | 0 | 0 | — | 0 | 0 |
Clinical Research Associate
View postingUnited States · last wk.
Clinical Project Manager
View postingCalifornia, United States · last mo.
Clinical Research Associate
View postingCalifornia, United States · last mo.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
NYSE provides pre-market update with insights on stocks, Alto Neuroscience financing, KPMG AI survey, and RSAC Conference.
High-Trend International Group appoints Christopher Nixon Cox as Chairman and Bo Cui as Chief Legal Officer, focusing on maritime decarbonization and global expansion.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Alto Neuroscience's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
